Item 2.02 - Results of Operations and Financial Condition: Charles River Laboratories will present at the J.P. Morgan 44th Annual Healthcare Conference on January 13, 2026, discussing the company's strategic focus, business developments, and recent trends. Preliminary Q4 2025 DSA Performance: Management disclosed that demand trends for the Discovery and Safety Assessment (DSA) business improved…

Our analysis rates this filing CAUTIOUS. The elevated concern level (6.2/10) reflects a company at an inflection point with meaningful execution risks offsetting positive demand signals. While DSA demand recovery is genuine (1.1x book-to-bill), management's flat revenue guidance for 2026 despite…

Concern level: HIGH (6.2/10). Key factors: Large Capital Deployment Risk: $510M K.F. Cambodia acquisition represents material capital commitment for vertical integration with execution risk, integration track record uncertainty, and unaddressed regulatory approval risk in Cambodia. Accretion projections ($0.25 in 2026, $0.60 in 2027) dependent on flawless execution.; DSA Demand Recovery…

Notable risk changes: Two significant acquisitions announced ($510M K.F. Cambodia + $60M PathoQuest) representing material capital deployment with integration execution risk and regulatory approval uncertainty; DSA segment showing demand recovery (1.1x book-to-bill Q4 2025) but 2026 guidance remains flat, indicating management skepticism about sustainability of improvement or conversion challenges; Manufacturing…

Positive surprise: DSA net book-to-bill of 1.1x in Q4 2025 indicates demand recovery (above prior weakness); Positive surprise: Company raising 2026 guidance to 'at least flat' organic growth after period of decline, with return to growth expected in H2 2026.

The model predicts CRL will underperform the S&P 500 by about 0.0% over 30 days (model confidence 65%). This is model analysis for research, not investment advice.